+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Omeros Corp (OMER) - Financial and Strategic SWOT Analysis Review

Omeros Corp (OMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Omeros Corp (Omeros) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Omeros Corp Key Recent Developments

  • May 10, 2024: Omeros to Announce First Quarter Financial Results on May 15, 2024
  • Feb 01, 2024: DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria, Updates Deployment and CAGR Guidance
  • Oct 19, 2023: Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
  • Jun 30, 2023: Omer Ashruf of Solon appointed to NEOMED Board of Trustees

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Omeros Corp - Key Facts
  • Omeros Corp - Key Employees
  • Omeros Corp - Key Employee Biographies
  • Omeros Corp - Major Products and Services
  • Omeros Corp - History
  • Omeros Corp - Company Statement
  • Omeros Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Omeros Corp - Business Description
  • R&D Overview
  • Omeros Corp - Corporate Strategy
  • Omeros Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Omeros Corp - Strengths
  • Omeros Corp - Weaknesses
  • Omeros Corp - Opportunities
  • Omeros Corp - Threats
  • Omeros Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Omeros Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 10, 2024: Omeros to Announce First Quarter Financial Results on May 15, 2024
  • Feb 01, 2024: DRI Healthcare Trust Announces the Expansion of its Royalty Entitlement on the US Net Sales of Omidria, Updates Deployment and CAGR Guidance
  • Oct 19, 2023: Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
  • Jun 30, 2023: Omer Ashruf of Solon appointed to NEOMED Board of Trustees
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Omeros Corp, Key Facts
  • Omeros Corp, Key Employees
  • Omeros Corp, Key Employee Biographies
  • Omeros Corp, Major Products and Services
  • Omeros Corp, History
  • Omeros Corp, Subsidiaries
  • Omeros Corp, Key Competitors
  • Omeros Corp, Ratios based on current share price
  • Omeros Corp, Annual Ratios
  • Omeros Corp, Interim Ratios
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Omeros Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Omeros Corp, Ratio Charts
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Seagen Inc
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • ValenzaBio Inc
  • Harrow Inc